Results of a dose-intense phase II study of a combination chemotherapy regimen with cisplatin (CDDP) and epirubicin (EPI) including medroxyprogesterone acetate (MPA) and recombinant interleukin 2 (rIL-2) in patients with inoperable primary lung cancer

✍ Scribed by Mantovani, G; Macciò, A; Massa, E; Mudu, M.C; Manca, G; Mulas, C; Massa, D; Succu, G; Astara, G; Massidda, S; Versace, R; Pisano, M

• Book ID: 118569718
• Publisher: Elsevier Science
• Year: 2000
• Tongue: English
• Weight: 105 KB
• Volume: 29
• Category: Article
• ISSN: 0169-5002
• DOI: 10.1016/s0169-5002(00)80173-7